2 completed, 1 recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Recruiting 1 |
Follow FOSTER®: new trials by email Literature Review of FOSTER® trials Research Report on FOSTER®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Beclometasone Dipropionate and Formoterol Inhalation Aerosol for Asthma Beclometasone Dipropionate and Formoterol Inhalation Aerosol, FOSTER® - Asthma (Diagnosis) | Phase 3 | Recruiting | Lunan Better Pharmaceutical Co., LTD. | 416 | 2026-06-08 | 2026-08-17 |
| Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN) CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo, Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Chiesi Farmaceutici S.p.A. | 750 | 2018-07-30 | 2026-05-12 |
| Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients CHF 1535 100/6 NEXT DPI® 2 months, CHF 1535 100/6 pMDI 2 months, BDP DPI 2 months - Asthma | Phase 3 | Completed | Chiesi Farmaceutici S.p.A. | 932 | 2011-03-01 | 2017-03-30 |
Asthma (2) · Disease (1) · Pulmonary Disease, Chronic Obstructive (1)
Chiesi Farmaceutici S.p.A. (2) · Lunan Better Pharmaceutical Co., LTD. (1)
China (2) · Poland (1)